Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
12/2003
12/04/2003US20030226169 DNA sequences encoding antifungal proteins
12/04/2003US20030225287 Synthesis of chiral 2-alkyl amino acids
12/04/2003US20030225279 Stavudine Polymorphic Form 1 process
12/04/2003US20030225277 9-(2-(2,4-cis(S)-4-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphor-inan-2 -yl)methoxyethyl)adenine by coupling the dichloridate of 9-(2-phosphonyl- methoxyethyl- or propyl)adenine (PMEA)(PMPA) with a 1-(chlorophenyl) propylene-1,3-diol
12/04/2003US20030225272 Novel mmp-2/mmp-9 inhibitors
12/04/2003US20030225271 Compounds useful as reversible inhibitors of cysteine proteases
12/04/2003US20030225270 E.g., 4-acetylamino-N-(1-((4-cyano-1-methylpiperidin-4-yl-carbamoyl)-2 -(cyclohexylethyl)benzamide; Alzheimer's, auto-immune and Crohn's diseases; atherosclerosis; antiarthritic agents; osteoporosis; atherosclerosis
12/04/2003US20030225269 Inhibitors of interleukin-1beta converting enzyme
12/04/2003US20030225151 Pyrazole compositions useful as inhibitors of ERK
12/04/2003US20030225147 Inhibit activity of protein kinases; for tumor growth, angiogenesis, viral infection, autoimmune disease or neurodegenerative disorder
12/04/2003US20030225138 3-(2,6-Dichloro-4-pyrydyl)-5-(substituted or nonsubstitutedbenzyl)- 2,4-imidazolidinedione derivatives useful for the treatment of inflammatory diseases
12/04/2003US20030225126 Bactericidal antimicrobial methods and compositions for use in treating gram positive infections
12/04/2003US20030225119 Crystalline fluoroquinolone arginine salt form
12/04/2003US20030225114 Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4- oxopyrimidines
12/04/2003US20030225107 Cyclopropyl containing oxazolidinone antibiotics and derivatives thereof
12/04/2003US20030225104 Pharmaceutical compositions for poorly soluble drugs
12/04/2003US20030225103 Method of using diketopiperazines and composition containing them
12/04/2003US20030225102 Dipeptidyl peptidase inhibitors; heterocyclic amide and semicarbazide derivatives, e.g., (2-Cyano-1-(piperazine-2-yl)-carbonyl pyrrolidine bis-trifluoroacetate
12/04/2003US20030225085 For reducing neuronal cell death in response to a traumatic event
12/04/2003US20030225077 Naphthylamines used to chronic inflammatory diseases.
12/04/2003US20030225075 Novel pyrimidone derivatives
12/04/2003US20030225071 N-heterocyclic amides and carbamates
12/04/2003US20030225070 Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles
12/04/2003US20030225066 Peritoneal dialysis solution with taurolidine
12/04/2003US20030225061 Protease inhibitors
12/04/2003US20030225056 Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
12/04/2003US20030225055 Having a 1-alkylpyrrolidine structure; 5-alkyl-2-thia-5-azabicyclo(2.2.1) heptan-3-ones or salts thereof useful as synthetic intermediates
12/04/2003US20030225051 Also estrogen phosphonates, thiophosphonates, sulphonates, sulphonamides, and N-acylsulfamates
12/04/2003US20030225042 Antipicornaviral compounds and compositions, their uses, and materials for their synthesis
12/04/2003US20030225029 Dosing regimen for gemcitabine HCV therapy
12/04/2003US20030225028 Beta-L-2'deoxy-nucleosides for the treatment of hepatitis B
12/04/2003US20030224987 Binding to formyl peptide receptor or formyl peptide receptor-like 1
12/04/2003US20030224982 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
12/04/2003US20030224980 Diagnostic reagents for human cytomegalovirus and methods of use
12/04/2003US20030224487 Novel cytokine zcytor17 ligand
12/04/2003US20030224483 Control of gene expression in eukaryotic cells
12/04/2003US20030224377 Novel LNA compositions and uses thereof
12/04/2003US20030224039 Infusing at a low temperature below the phase transition of lipid; use for intravenous administration, inhalation administration; no toxic solvents, simple process; bactericides
12/04/2003US20030224034 Personal care article and method for inhibiting attachment of yeast to skin
12/04/2003US20030224032 A substrate having a vapor deposited furanone compounds, covalent bonding through etherification or amination; protective coatings on medical equipment, seeds, fibrics, wool, hair, silk, cotton, chitin, collagen, animal
12/04/2003US20030224016 Transport peptides such as C-terminal Erns peptide and analogues thereof
12/04/2003US20030224014 Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor
12/04/2003US20030224012 Identifying a BASB033 polypeptide or an antibody that is immunospecific for such polypeptide, present with in a biological sample form the animal suspected having meningococcus induced infections and meningitis
12/04/2003US20030224002 Administering to a patient having a disorder associtaed with an intracellular pathogen, a molecular conjugate of a photosensitizer and a targeting moiety, wherein the targeting moiety targets conjugate to the pathogen or infected cell
12/04/2003US20030224000 Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
12/04/2003US20030223991 Modulating activity of the immune system using agonists or antagonists of a CD200 receptor. Also provided are methods of treatment and diagnosis of immune disorders.
12/04/2003US20030223987 Immunodeficiency recombinant poxvirus
12/04/2003US20030223972 Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
12/04/2003US20030223969 Method of modulating inflammatory response
12/04/2003US20030223964 Efficient expression of HIV polypeptides in a variety of cell types, including, but not limited to, mammalian, insect, and plant cells. Synthetic expression cassettes encoding the HIV Gag-containing polypeptides are described, as are uses of the
12/04/2003US20030223961 Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
12/04/2003US20030222461 Anti-panic opening system for doors
12/04/2003CA2490542A1 Fas peptide mimetics and uses thereof
12/04/2003CA2490062A1 Methods of treating bacterial infections and diseases associated therewith
12/04/2003CA2487732A1 Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
12/04/2003CA2487655A1 Methods and compositions for inhibiting hiv replication
12/04/2003CA2487557A1 Modulators and inhibitors of fibroblast growth factor receptor 5 polypeptides and gene expression thereof
12/04/2003CA2487452A1 A method for generating antigen-presenting cells
12/04/2003CA2487441A1 Novel uses of parapoxvirus preparations
12/04/2003CA2487073A1 Methods for using jnk inhibitors for treating or preventing disease-related wasting
12/04/2003CA2486853A1 Bis-aromatic alkanols
12/04/2003CA2486187A1 Kinase inhibitors
12/04/2003CA2486056A1 R-enantiomers of pyranoindole derivatives against hepatitis c
12/04/2003CA2485972A1 Method for the use of pyranoindole derivatives to treat infection with hepatitis c virus
12/04/2003CA2485825A1 Method for identification of a ligand whereby receptor residence time is measured
12/04/2003CA2485166A1 Substituted pyrimidinone and pyridinone compounds
12/04/2003CA2484822A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
12/04/2003CA2484274A1 Compositions and methods of use for a fibroblast growth factor
12/04/2003CA2459407A1 Crystalline fluoroquinolone arginine salt form
12/03/2003EP1367051A2 Inhibitors of tumor necrosis factor alpha
12/03/2003EP1367044A1 Calixarene-derivatives having anti-viral activity
12/03/2003EP1366783A1 Medicinal herbal preparation for disinfecting vaginas
12/03/2003EP1366768A1 Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
12/03/2003EP1366767A1 Aqueous suspension eyedrops and process for producing the same
12/03/2003EP1366180A2 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease
12/03/2003EP1366175A2 Multifunctional protease inhibitors and their use in treatment of disease
12/03/2003EP1366174A2 Sid polypeptides binding to pathogenic strain of the hepatitis c virus
12/03/2003EP1366167A2 Biological organism for preparing pharmaceutical compositions for treating mammals
12/03/2003EP1366165A2 G-protein coupled receptors
12/03/2003EP1366162A2 Putative proteins and nucleic acids encoding same
12/03/2003EP1366152A2 G-protein coupled receptors
12/03/2003EP1366146A2 Isolated nucleic acid molecules encoding a novel human signal transducing kinase-mapkap-2; encoded proteins, cells transformed therewith and uses thereof
12/03/2003EP1366144A2 A device for preparing cells
12/03/2003EP1366080A1 Natural antibodie active against hiv virus
12/03/2003EP1366079A2 Nuclear hormone receptor ligand binding domain
12/03/2003EP1366078A2 Ige receptor antagonists
12/03/2003EP1366075A2 New interferon beta-like molecules
12/03/2003EP1366068A1 Poynucleotide and polypeptide from group b streptococcus and use thereof for the preparation of a vaccine
12/03/2003EP1366066A2 Cyclohexapeptide having antimicrobial activity
12/03/2003EP1366065A1 Echinocandin derivatives, pharmaceutical compositions containing same and use thereof as drugs
12/03/2003EP1366064A1 Tumour targeting prodrugs activated by metallo matrixproteinases
12/03/2003EP1366055A2 Antiviral agents for treatment of flaviviridae infections
12/03/2003EP1366048A2 Pyrazolopyridine derivatives
12/03/2003EP1366047A1 Thiazole compounds as tgf-beta inhibitors
12/03/2003EP1366036A2 Compounds having activity as inhibitors of cytochrome p450rai
12/03/2003EP1366028A1 Diaminoquinazoline esters for use as dihydrofolate reductase inhibitors
12/03/2003EP1366024A2 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
12/03/2003EP1366021A2 Substituted diarylureas as stimulators for fas-mediated apoptosis
12/03/2003EP1365797A2 Methods and agents modulating upa/upar activity
12/03/2003EP1365781A1 Acrochordon alleviation
1 ... 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 ... 1798